Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.

Autor: Kosiborod MN; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA; School of Medicine, University of Missouri-Kansas City, Kansas City, MO, USA; The George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia. Electronic address: mkosiborod@saint-lukes.org., Esterline R; Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Furtado RHM; Academic Research Organization-Hospital Israelita Albert Einstein, Sao Paulo, Brazil; Instituto do Coracao do Hospital das Clinicas da FMUSP, Sao Paulo, Brazil., Oscarsson J; Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Gasparyan SB; Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Koch GG; Department of Biostatistics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA., Martinez F; National University of Córdoba, Córdoba, Argentina., Mukhtar O; Experimental Medicine and Immunotherapeutics Division, Department of Medicine, University of Cambridge, Cambridge, UK., Verma S; Division of Cardiac Surgery, Keenan Research Centre for Biomedical Science, Li Ka Shing Knowledge Institute of St Michael's Hospital, Toronto, ON, Canada; Department of Surgery and Department of Pharmacology and Toxicology, University of Toronto, Toronto, ON, Canada., Chopra V; Max Super Speciality Hospital, New Delhi, India., Buenconsejo J; Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, USA., Langkilde AM; Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Ambery P; Late-stage Development, CVRM, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden., Tang F; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA., Gosch K; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA., Windsor SL; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA., Akin EE; George Clinical Inc, Overland Park, KS, USA., Soares RVP; Academic Research Organization-Hospital Israelita Albert Einstein, Sao Paulo, Brazil., Moia DDF; Academic Research Organization-Hospital Israelita Albert Einstein, Sao Paulo, Brazil., Aboudara M; Division of Pulmonary and Critical Care, Saint Luke's Health System, Kansas City, MO, USA., Hoffmann Filho CR; Hospital Regional Hans Dieter Schmidt, Joinville, Brazil., Feitosa ADM; PROCAPE, Recife, Brazil., Fonseca A; Hospital Coracao do Brasil, Brasília, Brazil., Garla V; Department of Endocrinology, Diabetes and Metabolism, Internal Medicine, University of Mississippi Medical Center, Jackson, MS, USA; Mississippi Center for Clinical and Translational Research, Jackson, MI, USA., Gordon RA; North Shore University Health System, Evanston, IL, USA., Javaheri A; Washington University School of Medicine, St Louis, MO, USA., Jaeger CP; Hospital Mãe de Deus, Porto Alegre, Brazil., Leaes PE; Irmandade Da Santa Casa de Misericórdia de Porto Alegre, Brazil., Nassif M; Saint Luke's Mid America Heart Institute, Kansas City, MO, USA., Pursley M; Heart Group of the Eastern Shore, Fairhope, AL, USA., Silveira FS; Centro de Pesquisa Clínica do Coração, Aracaju, Brazil., Barroso WKS; Liga de Hipertensão Arterial -Universidade Federal de Goiás, Brazil; HCAMP-Secretaria Estadual de Saúde, Goiás, Brazil., Lazcano Soto JR; Instituto de Investigaciones Aplicadas a la Neurociencia AC, Durango City, Mexico., Nigro Maia L; Centro Integrado de Pesquisas, Hospital de Base, São José do Rio Preto, Brazil., Berwanger O; Academic Research Organization-Hospital Israelita Albert Einstein, Sao Paulo, Brazil.

Publikováno v: The lancet. Diabetes & endocrinology [Lancet Diabetes Endocrinol] 2021 Sep; Vol. 9 (9), pp. 586-594. Date of Electronic Publication: 2021 Jul 21.